Printed From BioPortfolio.com
Forteo Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis
10:08 EST 10 Nov 2017 | Speciality Pharma Journal
INDIANAPOLIS, Nov. 9, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new data showing that treatment with FORTEO® for 24 months was associated with significantly fewer vertebral and clinical fractures (a composite of painful vertebral and non-vertebral fractures) compared with risedronate, a widely used oral bisphosphonate, in postmenopausal women with severe osteoporosis …
Original Article: Forteo Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis
